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Introduction
In this issue of Breast Cancer Research Turken and
coworkers [1] describe an association between breast
cancer and autoimmune thyroid disease (AITD), showing
not only an increased prevalence of thyroid peroxidase
(TPO) antibodies in patients with breast cancer but also a
significantly increased rate of goiter (diffuse 8%, nodular
50%) as compared with control individuals (4% and 26%,
respectively). This finding is in agreement with previous
studies [2,3] that showed both increased goiter rates and
increased prevalence of thyroid enlargement by ultrasound
in patients with breast cancer [4]. This association repre-
sents yet another page in the continuing saga of the per-
ceived coincidence between breast cancer and diseases
of the thyroid gland. The fact that both breast cancer and
thyroid disease predominantly affect females and that both
have a postmenopausal peak incidence has inevitably
resulted in a search for an association between the two
diseases [5,6]. Although many studies have shown such
an association, evidence of specific causal linkage
between thyroid breast cancer and thyroid disease contin-
ues to be elusive.
One of the earliest reports on the association of breast
cancer with thyroid disease was that from Beatson [7] in
1896, who used oopherectomy and thyroid extract to treat
breast cancer. Since that report there have been many
studies showing an association of breast cancer with
hyperthyroidism, hypothyroidism, thyroxine replacement
therapy and thyroiditis [5,6]. Equally, other reports showed
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Abstract
A renewal of the search for a link between breast cancer and thyroid disease has once again
demonstrated an increased prevalence of autoimmune thyroid disease in patients with breast cancer.
This is the most recent of many studies showing an association between a variety of thyroid disorders
and breast cancer. Such an association is not surprising as both diseases are female predominant with
a similar postmenopausal peak incidence. The significance of the presence of thyroid autoantibodies,
particularly thyroid peroxidase antibodies, in serum from patients with breast cancer is unknown, but it
has been suggested that antibody positivity is associated with better prognosis. One area in which
thyroid and breast functions overlap is in the uptake and utilization of dietary iodide. Experimental
findings showing the ability of iodine or iodine-rich seaweed to inhibit breast tumour development is
supported by the relatively low rate of breast cancer in Japanese women who consume a diet
containing iodine-rich seaweed. However, there is as yet no direct evidence that iodine, iodinated
compounds, or a combination of iodine and selenium is the antimammary carcinogenic element in the
Japanese diet. It remains to be resolved whether the perceived breast cancer–thyroid disease
relationship is thyroid or iodine related or, in the case of thyroid autoantibodies, is the consequence of
an immune response to the carcinoma. Is this response breast specific and does it relate to iodine
status? These and many other questions await resolution before a definitive role in the natural history of
breast carcinoma can be assigned to the thyroid.
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no significant association. Where an association between
thyroid disease and breast cancer was shown to exist,
hypothyroidism was the most frequently observed finding.
In fact, many reports considered hyperthyroidism to be
protective against breast cancer because progression of
such cancers was more frequently observed when the
hyperthyroidism was treated [5].
The increased frequency of thyroid autoantibodies, TPO
antibodies and thyroglobulin antibodies described by
Turken and coworkers [1] in breast cancer patients as
compared with control individuals supports earlier findings
[8–11]. Such differences were not observed for other
autoimmune antibodies [9]. The use of specific immuno-
assays for TPO antibodies and thyroglobulin antibodies
[12] revealed an increased prevalence of TPO antibodies
in breast cancer. Although the presence of circulating
TPO antibodies in asymptomatic individuals has been
implicated as conferring an increased risk for future
hypothyroidism [13], there is no agreement on the signifi-
cance of its association with breast cancer [14]. A fivefold
excess in breast cancer has been reported in Japanese
patients with AITD [8]. However, no significant association
between breast cancer and Hashimoto’s thyroiditis was
reported in a study from the Mayo Clinic in the USA [15].
Thus, like other reported associations, the relationship
between AITD, iodine intake and breast cancer is far from
clear. Equally, there is little agreement on the significance
of any published association between a range of thyroid
disorders and breast cancer [5,6].
The possibility that hypothyroidism might in itself have
been beneficial in terms of outcome of breast cancer has
been suggested [16]. Recent reports from our laboratory
[11] have shown that the presence of TPO antibodies is
associated with a significant improvement in both disease-
free and overall outcome in breast cancer patients, and
that the magnitude of this prognostic effect was of a
similar order of magnitude to well established prognostic
indices for breast cancer such as axillary nodal status or
tumour size. Thus, we have the anomalous situation in
which the presence of TPO antibodies, while being asso-
ciated with breast cancer, also appears to confer prognos-
tic benefits. A recent review that contained a
meta-analysis of published work on breast–thyroid associ-
ations [14] found no significant association between the
two disorders and attributed any positive findings of such
an association to ‘selection or institutional referral bias’.
This negative finding was immediately followed by commu-
nications [1,17] reaffirming the association of breast
cancer with hypothyroidism and AITD. It is therefore
apparent that the argument about breast–thyroid associa-
tions is far from resolved.
The association of thyroid antibody positivity, sometimes
with transient thyroid dysfunction, has been reported in
the course of immunotherapy with recombinant cytokines
interleukin-2 and interferon-α for various cancers [18,19].
Thyroid antibody related hypothyroidism has been sug-
gested as being associated with a favourable tumour
response to such therapies. In a recent report [19] it was
shown in metastatic renal cell carcinoma that the presence
of a positive thyroid antibody titre, either pre-existing or
cytokine induced, was a highly significant independent
prognostic factor. In the case of thyroid autoantibodies
being associated with better disease outcome in breast
cancer, renal carcinoma or melanoma, it is possible that the
immune response to thyroid and tumour tissue might be
similarly regulated in that it might be directed against both
tumour and thyroid antigens. Another possibility is that both
tumour and thyroid share the same antigens because
expression of the sodium–iodide symporter has been
demonstrated in both thyroid and breast tissues [20–22].
One area in which thyroid and breast functions overlap is
in the uptake and utilization of iodide. In the thyroid, I– is
required for thyroid hormonogenesis whereas in the
breast I– is needed in breast milk as a source of neonatal
nutrition. Both organs require a method of oxidizing I– to I2
(organification) in order to produce iodoproteins [23,24].
This involves the presence of H2O2 as an oxidizing agent
catalyzed by TPO in the thyroid and by lactoperoxidases in
the breast. Apart from the requirement for iodide as a
nutrient in breast milk, there is no known role for iodine in
the normal or diseased breast. However, a breast require-
ment for I2 rather than I– has been suggested [25]. It has
been postulated that formation of iodolipids such as
iodolactones or iodoaldehydes represents a form of thy-
roidal autoregulation [26], which may be the mode of
action of iodide inhibition of thyroid function in the
Wolff–Chaikoff effect [27–29].
In addition to their role in inhibiting thyroid function, these
compounds may act as antiproliferative agents in the
thyroid [26]. Iodinated compounds (so-called XI) may
exert inhibitory effects on adenylate cyclase, NADPH
(nicotinamide adenine dinucleotide phosphate, reduced
form)-oxidase and TPO activities [27]. This effect seems
to require oxidation of I– to I2 because inhibitors of TPO or
I– trapping can reverse the inhibitory effect [29]. It has also
been suggested that such inhibitory actions of iodo-com-
pounds on cell proliferation might play a role in the breast
[30,31]. Some support for a role for iodine in the human
breast is provided by our own findings [20], which
showed that tissue iodine levels were relatively low in
patients with breast cancer as compared with normal
tissues or benign breast tumours (fibroadenomata). We
have also recently shown 125I uptake blocking effects in
sera from 19% of 105 patients with breast cancer [20], as
compared with a published prevalence of 30.7% of such
blocking activity, believed to be of immunogenic origin, in
Graves’ disease [32]. The ability of the breast to express237
sodium–iodide symporter [20–22] and, at least in lacta-
tion, to take up significant amounts of iodide has led to
studies of the potential for use of 131I ablative therapy in
breast cancer, analogous to that employed in the treat-
ment of hyperthyroidism or thyroid cancer.
An anticarcinogenic role for iodine in experimental animals
was suggested by the work of Funahashi and coworkers
[33], who found that administration of Lugol’s iodine or
iodine-rich Wakame seaweed to rats treated with the car-
cinogen dimethyl benzanthracene suppressed the devel-
opment of mammary tumours. In further studies [34], the
same group demonstrated that seaweed induced apopto-
sis in human breast cancer cells with greater potency than
that of fluorouracil, a chemotherapeutic agent used to
treat breast cancer. This finding led the authors to specu-
late that ‘seaweed may be applicable for prevention of
breast cancer’.
This hypothesis is in accord with the relatively low breast
cancer rate reported in Japan [35], where the normal diet
is seaweed rich, and with increasing breast cancer rates in
Japanese women who emigrate [36] or consume a
western style diet [37]. Interestingly this finding applies to
rates of breast cancer in both males and females [38].
This evidence favours the low rate of breast cancer being
environmental rather than genetic in origin. One of the
main dietary differences between Japanese and western
women is the consumption of large amounts of iodine-rich
seaweeds by the former, yielding a dietary iodine intake of
several milligrams per day in Japanese women as com-
pared with microgram quantities in western women [31].
Of course it must be stressed that all this evidence is cir-
cumstantial because the contribution, if any, of dietary
iodine intake to these findings is unknown. Equally, the
possibility that this protective effect may be lost in patients
with AITD [8] remains to be explored.
The frequent coexistence of iodine and selenium deficien-
cies and the importance of replacing both to maintain
thyroid function is well established [39]. It has also been
suggested that a combined iodine–selenium deficiency
may facilitate the development of breast cancer [31]. Sele-
nium deficiency results in diminution of selenium-contain-
ing antioxidative enzymes such as glutathione peroxidase,
deiodinases and thioredoxine reductases [39,40], leading
to increased levels of reactive oxygen species. These oxi-
dants can inactivate many enzymes, are a feature of lipid
peroxidation and DNA damage, and have been shown to
be associated with carcinogenesis in the breast [41]. On
the other hand, increased serum levels of antioxidants
have been associated with reductions in breast cancer
risk [42]. There is also some evidence that iodide itself
may act as an antioxidant [43]. Selenium deficiency is
associated with AITD perhaps as a result of increased
inflammatory activity arising from decreased activity of
selenium containing antioxidative enzymes such as glu-
tathione peroxidase [39], whereas increasing dietary sele-
nium or administration of selenomethionine have also been
reported to diminish TPO antibody levels [44,45].
Although there is as yet no definitive evidence of a role for
the thyroid in the natural history of breast cancer, the con-
tinuing reports of an association such as that in this issue
of Breast Cancer Research [1] should not be ignored. In
particular, the question of whether the presence of TPO
antibodies in serum of patients with breast cancer is
breast specific or part of a generalized immunogenic
response needs to be explored. Also requiring study are
the involvement of iodide transport in the breast and addi-
tional roles for iodinated compounds within the mammary
glands, with their accompanying benefit of providing a
new therapeutic pathway for radioiodine ablative therapy.
Finally, it remains to be established whether iodide or sele-
nium treatment has prophylactic potential. Whatever the
future study pathways, there is little doubt that the per-
ceived association of two of the most common female dis-
orders will continue to intrigue investigators.
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